269 related articles for article (PubMed ID: 20924102)
1. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma.
Klages K; Mayer CT; Lahl K; Loddenkemper C; Teng MW; Ngiow SF; Smyth MJ; Hamann A; Huehn J; Sparwasser T
Cancer Res; 2010 Oct; 70(20):7788-99. PubMed ID: 20924102
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic depletion of CCR8
Van Damme H; Dombrecht B; Kiss M; Roose H; Allen E; Van Overmeire E; Kancheva D; Martens L; Murgaski A; Bardet PMR; Blancke G; Jans M; Bolli E; Martins MS; Elkrim Y; Dooley J; Boon L; Schwarze JK; Tacke F; Movahedi K; Vandamme N; Neyns B; Ocak S; Scheyltjens I; Vereecke L; Nana FA; Merchiers P; Laoui D; Van Ginderachter JA
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33589525
[TBL] [Abstract][Full Text] [Related]
3. Regulatory T-cell depletion synergizes with gp96-mediated cellular responses and antitumor activity.
Yan X; Zhang X; Wang Y; Li X; Wang S; Zhao B; Li Y; Ju Y; Chen L; Liu W; Meng S
Cancer Immunol Immunother; 2011 Dec; 60(12):1763-74. PubMed ID: 21789592
[TBL] [Abstract][Full Text] [Related]
4. Transgene IL-6 enhances DC-stimulated CTL responses by counteracting CD4+25+Foxp3+ regulatory T cell suppression via IL-6-induced Foxp3 downregulation.
Bhanumathy KK; Zhang B; Ahmed KA; Qureshi M; Xie Y; Tao M; Tan X; Xiang J
Int J Mol Sci; 2014 Mar; 15(4):5508-21. PubMed ID: 24690994
[TBL] [Abstract][Full Text] [Related]
5. Caloric Restriction Impairs Regulatory T cells Within the Tumor Microenvironment After Radiation and Primes Effector T cells.
Manukian G; Kivolowitz C; DeAngelis T; Shastri AA; Savage JE; Camphausen K; Rodeck U; Zarif JC; Simone NL
Int J Radiat Oncol Biol Phys; 2021 Aug; 110(5):1341-1349. PubMed ID: 33647370
[TBL] [Abstract][Full Text] [Related]
6. Prophylactic DNA vaccine targeting Foxp3
Namdar A; Mirzaei R; Memarnejadian A; Boghosian R; Samadi M; Mirzaei HR; Farajifard H; Zavar M; Azadmanesh K; Elahi S; Noorbakhsh F; Rezaei A; Hadjati J
Cancer Immunol Immunother; 2018 Mar; 67(3):367-379. PubMed ID: 29124314
[TBL] [Abstract][Full Text] [Related]
7. Transient Treg depletion enhances therapeutic anti-cancer vaccination.
Fisher SA; Aston WJ; Chee J; Khong A; Cleaver AL; Solin JN; Ma S; Lesterhuis WJ; Dick I; Holt RA; Creaney J; Boon L; Robinson B; Lake RA
Immun Inflamm Dis; 2017 Mar; 5(1):16-28. PubMed ID: 28250921
[TBL] [Abstract][Full Text] [Related]
8. Tumor-infiltrating regulatory T cells inhibit endogenous cytotoxic T cell responses to lung adenocarcinoma.
Ganesan AP; Johansson M; Ruffell B; Yagui-Beltrán A; Lau J; Jablons DM; Coussens LM
J Immunol; 2013 Aug; 191(4):2009-17. PubMed ID: 23851682
[TBL] [Abstract][Full Text] [Related]
9. Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients.
Ridolfi L; Petrini M; Granato AM; Gentilcore G; Simeone E; Ascierto PA; Pancisi E; Ancarani V; Fiammenghi L; Guidoboni M; de Rosa F; Valmorri L; Scarpi E; Nicoletti SV; Baravelli S; Riccobon A; Ridolfi R
J Transl Med; 2013 May; 11():135. PubMed ID: 23725550
[TBL] [Abstract][Full Text] [Related]
10. Regulatory T cells control endothelial chemokine production and migration of T cells into intestinal tumors of APC
Akeus P; Szeponik L; Ahlmanner F; Sundström P; Alsén S; Gustavsson B; Sparwasser T; Raghavan S; Quiding-Järbrink M
Cancer Immunol Immunother; 2018 Jul; 67(7):1067-1077. PubMed ID: 29671006
[TBL] [Abstract][Full Text] [Related]
11. Blocking retinoic acid receptor-α enhances the efficacy of a dendritic cell vaccine against tumours by suppressing the induction of regulatory T cells.
Galvin KC; Dyck L; Marshall NA; Stefanska AM; Walsh KP; Moran B; Higgins SC; Dungan LS; Mills KH
Cancer Immunol Immunother; 2013 Jul; 62(7):1273-82. PubMed ID: 23657628
[TBL] [Abstract][Full Text] [Related]
12. Single administration of low dose cyclophosphamide augments the antitumor effect of dendritic cell vaccine.
Liu JY; Wu Y; Zhang XS; Yang JL; Li HL; Mao YQ; Wang Y; Cheng X; Li YQ; Xia JC; Masucci M; Zeng YX
Cancer Immunol Immunother; 2007 Oct; 56(10):1597-604. PubMed ID: 17440723
[TBL] [Abstract][Full Text] [Related]
13. Skin tumor responsiveness to interleukin-2 treatment and CD8 Foxp3+ T cell expansion in an immunocompetent mouse model.
Foureau DM; McKillop IH; Jones CP; Amin A; White RL; Salo JC
Cancer Immunol Immunother; 2011 Sep; 60(9):1347-56. PubMed ID: 21638127
[TBL] [Abstract][Full Text] [Related]
14. Bcl6 Preserves the Suppressive Function of Regulatory T Cells During Tumorigenesis.
Li Y; Wang Z; Lin H; Wang L; Chen X; Liu Q; Zuo Q; Hu J; Wang H; Guo J; Xie L; Tang J; Li Z; Hu L; Xu L; Zhou X; Ye L; Huang Q; Xu L
Front Immunol; 2020; 11():806. PubMed ID: 32477338
[TBL] [Abstract][Full Text] [Related]
15. Both intratumoral regulatory T cell depletion and CTLA-4 antagonism are required for maximum efficacy of anti-CTLA-4 antibodies.
Lax BM; Palmeri JR; Lutz EA; Sheen A; Stinson JA; Duhamel L; Santollani L; Kennedy A; Rothschilds AM; Spranger S; Sansom DM; Wittrup KD
Proc Natl Acad Sci U S A; 2023 Aug; 120(31):e2300895120. PubMed ID: 37487077
[TBL] [Abstract][Full Text] [Related]
16. Regulatory T cells inhibit Fas ligand-induced innate and adaptive tumour immunity.
Simon AK; Jones E; Richards H; Wright K; Betts G; Godkin A; Screaton G; Gallimore A
Eur J Immunol; 2007 Mar; 37(3):758-67. PubMed ID: 17294404
[TBL] [Abstract][Full Text] [Related]
17. CD25-T
Solomon I; Amann M; Goubier A; Arce Vargas F; Zervas D; Qing C; Henry JY; Ghorani E; Akarca AU; Marafioti T; Śledzińska A; Werner Sunderland M; Franz Demane D; Clancy JR; Georgiou A; Salimu J; Merchiers P; Brown MA; Flury R; Eckmann J; Murgia C; Sam J; Jacobsen B; Marrer-Berger E; Boetsch C; Belli S; Leibrock L; Benz J; Koll H; Sutmuller R; Peggs KS; Quezada SA
Nat Cancer; 2020 Dec; 1(12):1153-1166. PubMed ID: 33644766
[TBL] [Abstract][Full Text] [Related]
18. Anti-tumor immunity and autoimmunity: a balancing act of regulatory T cells.
Wei WZ; Morris GP; Kong YC
Cancer Immunol Immunother; 2004 Feb; 53(2):73-8. PubMed ID: 14610619
[TBL] [Abstract][Full Text] [Related]
19. Celastrol, which targets IL-2/CD25 binding inhibition, induces T cell-mediated antitumor activity in melanoma.
Cho O; Lee JW; Jeong YJ; Kim LK; Jung BK; Heo TH
Eur J Pharmacol; 2024 Jan; 962():176239. PubMed ID: 38043776
[TBL] [Abstract][Full Text] [Related]
20. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells.
Kong LY; Wei J; Sharma AK; Barr J; Abou-Ghazal MK; Fokt I; Weinberg J; Rao G; Grimm E; Priebe W; Heimberger AB
Cancer Immunol Immunother; 2009 Jul; 58(7):1023-32. PubMed ID: 19002459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
